Vanguard Group Inc. Acquires 561,978 Shares of Intellia Therapeutics, Inc. $NTLA

Vanguard Group Inc. raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 5.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,752,031 shares of the company’s stock after purchasing an additional 561,978 shares during the period. Vanguard Group Inc. owned 10.38% of Intellia Therapeutics worth $76,447,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Invesco Ltd. increased its position in Intellia Therapeutics by 4.0% during the 4th quarter. Invesco Ltd. now owns 96,434 shares of the company’s stock valued at $1,124,000 after buying an additional 3,677 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Intellia Therapeutics by 10.6% in the fourth quarter. Legal & General Group Plc now owns 106,767 shares of the company’s stock worth $1,245,000 after acquiring an additional 10,211 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Intellia Therapeutics during the fourth quarter valued at $1,151,000. Raymond James Financial Inc. purchased a new position in shares of Intellia Therapeutics in the 4th quarter worth about $4,793,000. Finally, Barclays PLC boosted its stake in Intellia Therapeutics by 6.4% in the 4th quarter. Barclays PLC now owns 311,632 shares of the company’s stock worth $3,634,000 after purchasing an additional 18,837 shares in the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on NTLA shares. Chardan Capital reduced their price objective on shares of Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Wedbush reissued a “neutral” rating and set a $7.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 16th. Royal Bank Of Canada lowered their price objective on Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. HC Wainwright cut their target price on Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Wells Fargo & Company restated an “overweight” rating and issued a $45.00 price target (down previously from $50.00) on shares of Intellia Therapeutics in a research note on Friday, August 8th. Twelve research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.05.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, Director William J. Chase purchased 100,000 shares of Intellia Therapeutics stock in a transaction dated Wednesday, August 20th. The stock was purchased at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the transaction, the director directly owned 134,693 shares of the company’s stock, valued at $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the transaction, the executive vice president owned 106,062 shares in the company, valued at $1,486,989.24. This trade represents a 6.57% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,534 shares of company stock valued at $153,837. Corporate insiders own 3.10% of the company’s stock.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $10.52 on Friday. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -2.24 and a beta of 2.31. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $24.16. The business’s fifty day moving average price is $11.08 and its 200-day moving average price is $9.52.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.04. The company had revenue of $14.25 million during the quarter, compared to analyst estimates of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.Intellia Therapeutics’s revenue was up 104.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.52) earnings per share. Equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.